Targeting KRAS-mutant stomach/colorectal tumours by disrupting the ERK2-p53 complex
Xiang Wang(University of Science and Technology of China), Jing‐Yu Lang(The University of Texas MD Anderson Cancer Center), Qing Chen(Memorial Sloan Kettering Cancer Center), Dandan Liu(Kunming Medical University), Yongfeng Zhang(Jilin University), Feng Jiang(Zhejiang Cancer Hospital), Xiangyin Kong(Chinese Center For Disease Control and Prevention), Jiayan Shen(Hangzhou Normal University), Leizhen Zheng(Shanghai Jiao Tong University), Qing Xie(Nanchang University)
Cited by 0
Related Papers
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
FUNDC1 protects against doxorubicin-induced cardiomyocyte PANoptosis through stabilizing mtDNA via interaction with TUFM
|Cell Death and Disease|2022|139
APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis
|Journal of Clinical Investigation|2011|132